ResMed Inc. financials

RMD CIK 0000943819

Source: EDGAR filings · Built 2026-08-15T00:22:03Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Free Cash Flow 1.65B 1.66B 1.30B 573.63M 216.31M 634.01M
EBITDA 2.09B 1.88B 1.50B 1.30B 1.16B 1.06B
Working Capital 2.93B 2.49B 1.45B 1.61B 1.24B 662.99M
Net Debt -643.32M -357.64M 635.57M 1.35B 643.84M 498.44M
Gross Margin 61.06% 59.36% 56.67% 55.78% 56.57% 57.53%
Operating Margin 33.37% 32.75% 28.17% 26.80% 27.96% 28.27%
Net Margin 26.94% 27.22% 21.79% 21.25% 21.78% 14.84%
Return on Equity (ROE) 23.13% 23.47% 20.99% 21.73% 23.19% 16.44%
Return on Assets (ROA) 16.99% 17.14% 14.86% 13.29% 15.30% 10.04%
Current Ratio 3.10× 3.44× 2.59× 3.12× 2.80× 1.73×
Debt-to-Equity 0.13× 0.14× 0.18× 0.38× 0.27× 0.28×
Effective Tax Rate 20.64% 16.50% 19.28% 18.53% 18.85% 46.30%
Cash Conversion Ratio 1.19× 1.25× 1.37× 0.77× 0.45× 1.55×
Accruals Ratio -0.03× -0.04× -0.06× 0.03× 0.08× -0.06×
SBC % of Revenue 1.85% 1.78% 1.71% 1.68% 1.82% 2.00%
CapEx Coverage 11.55× 19.49× 14.09× 5.79× 2.60× 7.17×
Free Cash Flow Per Share $11.29 $11.28 $8.82 $3.89 $1.47 $4.33

Income Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 5.65B 5.15B 4.69B 4.22B 3.58B 3.20B
Cost of Goods and Services Sold 2.20B 2.09B 2.03B 1.87B 1.55B 1.36B
Gross Profit 3.45B 3.05B 2.66B 2.36B 2.02B 1.84B
Research and Development Expense 378.29M 331.28M 307.52M 287.64M 253.57M 225.28M
Selling, General and Administrative Expense 1.12B 993.05M 917.14M 874.00M 737.51M 670.39M
Operating Expenses 1.57B 1.37B 1.34B 1.22B 1.02B 935.42M
Operating Income (Loss) 1.89B 1.69B 1.32B 1.13B 1.00B 903.68M
Income Tax Expense (Benefit) 396.12M 276.84M 243.85M 204.11M 181.05M 409.16M
Net Income (Loss) Attributable to Parent 1.52B 1.40B 1.02B 897.56M 779.44M 474.50M
Earnings Per Share, Basic $10.47 $9.55 $6.94 $6.12 $5.34 $3.27
Weighted Average Number of Shares Outstanding, Basic 145.52M 146.72M 147.02M 146.76M 146.07M 145.31M
Earnings Per Share, Diluted $10.43 $9.51 $6.92 $6.09 $5.30 $3.24
Weighted Average Number of Shares Outstanding, Diluted 146.05M 147.34M 147.55M 147.46M 147.04M 146.45M

Balance Sheet

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 1.47B 1.21B 238.36M 227.89M 273.71M 295.28M
Assets, Current 4.32B 3.51B 2.36B 2.37B 1.93B 1.57B
Assets 8.97B 8.17B 6.87B 6.75B 5.10B 4.73B
Long-term Debt 399.42M 658.39M 697.31M 1.43B 765.33M 643.35M
Liabilities, Current 1.40B 1.02B 910.65M 758.53M 689.30M 911.77M
Liabilities 2.38B 2.21B 2.01B 2.62B 1.74B 1.84B
Stockholders' Equity Attributable to Parent 6.59B 5.97B 4.86B 4.13B 3.36B 2.89B
Common Stock, Shares, Outstanding 144.24M 146.39M 146.90M 147.06M 146.41M 145.65M

Cash Flow Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 1.81B 1.75B 1.40B 693.30M 351.15M 736.72M
Payments to Acquire Property, Plant, and Equipment 156.28M 89.86M 99.46M 119.67M 134.84M 102.71M
Net Cash Provided by (Used in) Investing Activities -545.20M -200.04M -269.78M -1.16B -229.92M -158.46M
Payments for Repurchase of Common Stock 700.04M 300.02M 150.01M 0 0
Payments of Dividends 349.66M 310.88M 282.32M 258.28M 245.34M 226.71M
Net Cash Provided by (Used in) Financing Activities -1.01B -606.25M -1.12B 422.87M -128.36M -764.63M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RMD CIK 0000943819), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

THC

TENET HEALTHCARE CORP

CI

The Cigna Group

INCY

INCYTE CORPORATION